The study validated the preimplantation genetic testing for aneuploidy (PGT-A) platform at Juno, which is the reference lab that performs the majority of PGT-A at RMA. This study determined that when this platform calls an embryo, “abnormal,” meaning that it has either missing or additional chromosomes, that the test is accurate in doing so. Furthermore, this study updated our ability to look at the impact of the embryo biopsy procedure and continued to illustrate that the procedure at RMA is not harmful to embryos.